Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 8/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | CDC25B | P30305 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | CTSV | O60911 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15375553 | 1.00 | LMNA (0.55) | LMNAL3MBTL1GRM2PTPN1CDC25B | |
| SCHEMBL15375475 | 1.00 | LMNA (0.55) | LMNAL3MBTL1GRM2PTPN1CDC25B | |
| SCHEMBL2823472 | 0.82 | GRM2 (0.68) | LMNAGRM2 | |
| SCHEMBL9752599 | 0.80 | LMNA (0.51) | LMNAL3MBTL1GRM2PTPN1CDC25B | |
| SCHEMBL11233634 | 0.78 | GRM2 (0.58) | LMNAGRM2 | |
| SCHEMBL15375534 | 0.78 | LMNA (0.49) | LMNAL3MBTL1GRM2PTPN1CDC25B | |
| SCHEMBL11230811 | 0.76 | GRM2 (0.65) | GRM2 | |
| SCHEMBL3142790 | 0.75 | LMNA (0.63) | LMNAL3MBTL1PTPN1CDC25BTAAR1 | |
| SCHEMBL1269318 | 0.75 | GRM2 (0.51) | LMNAGRM2 | |
| SCHEMBL9872188 | 0.74 | LMNA (0.57) | LMNAL3MBTL1PTPN1CDC25BTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284306-B2 | (R)-Nifuratel, its use for the treatment of infections and synthesis of (R) and (S)-Nifuratel | POLICHEM SA (LU) | 2016-03-15 | — | — | US | disclosed |
| US-9067927-B2 | (R)-Nifuratel, its use for the treatment of infections and synthesis of (R) and (S)-Nifuratel | POLICHEM SA (LU) | 2015-06-30 | — | — | US | disclosed |
| US-20150148547-A1 | (R)-Nifuratel, its use for the treatment of infections and synthesis of (R) and (S)-Nifuratel | POLICHEM SA (LU) | 2015-05-28 | — | — | US | disclosed |
| US-20150119431-A1 | (R)-Nifuratel, its use for the treatment of infections and synthesis of (R) and (S)-Nifuratel | POLICHEM SA (LU) | 2015-04-30 | — | — | US | disclosed |
| EP-2847189-A1 | (R) -NIFURATEL, ITS USE FOR THE TREATMENT OF INFECTIONS AND SYNTHESIS OF (R) AND (S) -NIFURATEL | Polichem SA (LU) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013167295-A1 | (R) -NIFURATEL, ITS USE FOR THE TREATMENT OF INFECTIONS AND SYNTHESIS OF (R) AND (S) -NIFURATEL | POLICHEM SA (LU) | 2013-11-14 | — | — | WO | disclosed |
| EP-2662371-A1 | (R)-Nifuratel and synthesis of (R) and (S)-Nifuratel | Polichem SA (LU) | 2013-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119431-A1 | (R)-Nifuratel, its use for the treatment of infections and synthesis of (R) and (S)-Nifuratel | BLVRB, NRDC, NISCH | LMNA 4327/4885L3MBTL1 1160/4885GRM2 4126/4885 |
| US-20150148547-A1 | (R)-Nifuratel, its use for the treatment of infections and synthesis of (R) and (S)-Nifuratel | BLVRB, NRDC, NISCH | LMNA 4327/4885L3MBTL1 1160/4885GRM2 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.